Published in

Oxford University Press, Carcinogenesis: Integrative Cancer Research, 2(33), p. 452-458, 2011

DOI: 10.1093/carcin/bgr271

Links

Tools

Export citation

Search in Google Scholar

EPHA7, a new target gene for 6q deletion in T-cell lymphoblastic lymphomas.

This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Cryptic deletions at chromosome 6q are common cytogenetic abnormalities in T-cell lymphoblastic leukemia/lymphoma (T-LBL), but the target genes have not been formally identified. Our results build on detection of specific chromosomal losses in a mouse model of ¿-radiation-induced T-LBLs and provide interesting clues for new putative susceptibility genes in a region orthologous to human 6q15-6q16.3. Among these, Epha7 emerges as a bona fide candidate tumor suppressor gene because it is inactivated in practically all the T-LBLs analyzed (100% in mouse and 95.23% in human). We provide evidence showing that Epha7 downregulation may occur, at least in part, by loss of heterozygosity (19.35% in mouse and 12.5% in human) or promoter hypermethylation (51.61% in mouse and 43.75% in human) or a combination of both mechanisms (12.90% in mouse and 6.25% in human). These results indicate that EPHA7 might be considered a new tumor suppressor gene for 6q deletions in T-LBLs. Notably, this gene is located in 6q16.1 proximal to GRIK2 and CASP8AP2, other candidate genes identified in this region. Thus, del6q seems to be a complex region where inactivation of multiple genes may cooperatively contribute to the onset of T-cell lymphomas. ; Spanish Ministry of Education and Science (SAF2009-11426) ; European Commission (FI6R-CT-2003-508842) ; Ministerio de Ciencia e Innovación (SAF2009-11426) ; Centro de Biología Molecular Universidad Autónoma de Madrid group is supported by the Centro de Investigaciones Biomédicas en Red de Enfermedades Raras network from the MICINN ; Peer Reviewed